Do I need a prescription for Phenelzine 15mg tablets?

Phenelzine 15mg tablets is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Phenelzine 15mg tablets?

Phenelzine 15mg tablets is the generic name. It is available under brand names including: Nardil 15mg tablets, Phenelzine 15mg tablets, Phenelzine 15mg tablets. (Source: NHS dm+d — Actual Medicinal Products)

Phenelzine 15mg tablets

Prescription only

Requires a prescription from a doctor or prescriber

Tablet

15mg

Oral

Antidepressant drugs

Active ingredients:

Phenelzine

BNF classificationBrowse formulary

Where this medicine sits in the British National Formulary — the UK's standard prescribing reference

BNF 04.03.02

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC N06AF03

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Phenelzine

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Phenelzine

Source: MHRA Products DatabaseOGL 3.0

Updated 3 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Phenelzine

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Phenelzine

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

3 branded products available

3 productsShow details

3 products

Possibly available on the UK marketDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Phenelzine on the MHRA register

Phenelzine 15mg tablets

Neon Healthcare Ltd

Nardil 15mg tablets

Neon Healthcare Ltd

Discontinued

Phenelzine 15mg tablets

Special Order

None

Discontinued

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Price & daily doseShow details

£236.40indicative price

This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.

View full Drug Tariff

Source: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.

WHO defined daily dose (DDD)

60 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

10 similarShow details

Phenelzine 15mg capsules

Capsule

15mg

Same therapeutic group

Isocarboxazid 20mg/5ml oral suspension

Oral suspension

20mg/5ml

Same therapeutic group

Isocarboxazid 10mg tablets

Tablet

10mg

Same therapeutic group

Tranylcypromine 10mg tablets

Tablet

10mg

Same therapeutic group

Citalopram 30mg tablets

Tablet

30mg

Same BNF section

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Show details

Loading prescribing data...

Clinical guidelines and formulary information

British National Formulary

Phenelzine

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

NICE clinical guidance(3)

Social anxiety disorder: recognition, assessment and treatment (CG159)

CG159

Clinical guideline

Updated May 2013

Depression in adults with a chronic physical health problem: recognition and management (CG91)

CG91

Clinical guideline

Updated Oct 2009

Depression in adults: treatment and management (NG222)

NG222

NICE guideline

Updated Jun 2022

Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Phenelzine

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

42277211000001109

dm+d ID

42277211000001109

VTM (Virtual Therapeutic Moiety)

777159006

VMP (Virtual Medicinal Product)

42277211000001109

BNF code

04030200

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

N06AF03

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

145 found

Half-life

11.6 hours

Mechanism

The basic mechanism of action of phenelzine acts as an inhibitor and substrate o…

Food interactions

4 warnings

Human targets

7 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

19.8 ng/ml

Phenelzine is rapidly absorbed from the gastrointestinal tract.…

Half-life

11.6 hours

After administration phenelzine presents a very short half-life of 11.6 hours in humans.
[L1365]

Protein binding

Unchanged phenelzine presents a high protein binding which reduced its bioavailability.T114

Volume of distribution

The volume of distribution of phenelzine is hard to determine as drugs from this kind penetrate the CNS very well into the tissue where their activity is desired.T113…

Metabolism

For the metabolic studies, it is assumed that phenelzine is acetylated.…

Elimination

79%

The elimination of the administered dose is mainly composed of the phenelzine metabolites, phenylacetic acid and parahydroxyphenylacetic acid…

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder.[A15753] It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name of Nardil.

Properties:

liquid

Avg. mass: 136.19 Da

View FDA drug label

DrugBank indication

Phenelzine is indicated for the treatment of nonendogenous, neurotic or atypical depression for patients that do not tolerate other forms of therapy.
[L1356]

Atypical depression has a high prevalence rate, starts in early life, tends to last longer, is more likely to occur in people with bipolar disorder, has a high comorbidity with anxiety disorder and carries more risk of suicidal behavior. It is important to specify the atypical feature to predict the clinical course of depression and hence generate the best treatment and service. The featuring symptoms of the atypical feature include mood reactivity, two or more of this symptoms: 1) increased appetite, 2) increased sleep, 3) leaden paralysis and 4) interpersonal rejection sensitivity and should not have melancholic or catatonic features of depression.
[A31917]

Neurotic depression is a depression of an emotionally unstable person.

It is a secondary condition to major personality disorder, neuroses and drug use disorders. Likewise, a primary depression with a family history of depression spectrum disease would fit in this category.
[A31922]

A nonendogenous depression is characterized by a disturbance in mood and general outlook. The physical symptoms tend to be less severe and it often occurs in response to stressful life events that keep occurring over a large period of time generating a continuous stress in the daily living.
[A31924]

Also known as(132)

Fenelzina

Phenelzin

Phenelzine

Phénelzine

Phenelzinum

1.4.3.21

1.4.3.4

MAO-A

Dosage forms(4)

Tablet, film coated (Oral)

Tablet (Oral) — 15 mg

Tablet, film coated (Oral) — 15 mg/1

Tablet (Oral) — 15 mg/1

Molecular properties(18)

Drug interactions(1763)

Known interactions with other medications. Always consult a healthcare professional.

Risperidone

Moderate

DB00734

Phenelzine may increase the hypotensive activities of Risperidone.

Check this interaction

Cilostazol

Unknown severity

DB01166

The serum concentration of Cilostazol can be increased when it is combined with Phenelzine.

Check this interaction

Doxylamine

Moderate

DB00366

Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Phenelzine.

Check this interaction

Dronabinol

Unknown severity

DB00470

The serum concentration of Dronabinol can be increased when it is combined with Phenelzine.

Check this interaction

Droperidol

Moderate

DB00450

Droperidol may increase the central nervous system depressant (CNS depressant) activities of Phenelzine.

Check this interaction

Hydroxyzine

Moderate

DB00557

Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Phenelzine.

Check this interaction

Magnesium sulfate

Moderate

DB00653

The therapeutic efficacy of Phenelzine can be increased when used in combination with Magnesium sulfate.

Check this interaction

Methotrimeprazine

Moderate

DB01403

Phenelzine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.

Check this interaction

Metyrosine

Moderate

DB00765

Phenelzine may increase the sedative activities of Metyrosine.

Check this interaction

Minocycline

Moderate

DB01017

Minocycline may increase the central nervous system depressant (CNS depressant) activities of Phenelzine.

Check this interaction

Nabilone

Moderate

DB00486

Nabilone may increase the central nervous system depressant (CNS depressant) activities of Phenelzine.

Check this interaction

Orphenadrine

Moderate

DB01173

Phenelzine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.

Check this interaction

Paraldehyde

Moderate

DB09117

Phenelzine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.

Check this interaction

Perampanel

Moderate

DB08883

Perampanel may increase the central nervous system depressant (CNS depressant) activities of Phenelzine.

Check this interaction

Pramipexole

Moderate

DB00413

Phenelzine may increase the sedative activities of Pramipexole.

Check this interaction

Ropinirole

Moderate

DB00268

Phenelzine may increase the sedative activities of Ropinirole.

Check this interaction

Rotigotine

Moderate

DB05271

Phenelzine may increase the sedative activities of Rotigotine.

Check this interaction

Rufinamide

Unknown severity

DB06201

The risk or severity of adverse effects can be increased when Rufinamide is combined with Phenelzine.

Check this interaction

Sodium oxybate

Moderate

DB09072

Phenelzine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.

Check this interaction

Suvorexant

Moderate

DB09034

Phenelzine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.

Check this interaction

Thalidomide

Moderate

DB01041

Phenelzine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.

Check this interaction

Zolpidem

Moderate

DB00425

Phenelzine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.

Check this interaction

Eliglustat

Moderate

DB09039

The metabolism of Eliglustat can be decreased when combined with Phenelzine.

Check this interaction

Ibrutinib

Moderate

DB09053

The metabolism of Ibrutinib can be decreased when combined with Phenelzine.

Check this interaction

Succinylcholine

Moderate

DB00202

Phenelzine may increase the neuromuscular blocking activities of Succinylcholine.

Check this interaction

Phenmetrazine

Unknown severity

DB00830

The risk or severity of hypertension can be increased when Phenelzine is combined with Phenmetrazine.

Check this interaction

Ephedrine

Unknown severity

DB01364

The risk or severity of hypertension can be increased when Phenelzine is combined with Ephedrine.

Check this interaction

Epicaptopril

Unknown severity

DB02032

The risk or severity of hypertension can be increased when Phenelzine is combined with Epicaptopril.

Check this interaction

Taxifolin

Unknown severity

DB02224

The risk or severity of hypertension can be increased when Phenelzine is combined with Taxifolin.

Check this interaction

1-benzylimidazole

Unknown severity

DB04581

The risk or severity of hypertension can be increased when Phenelzine is combined with 1-benzylimidazole.

Check this interaction

Amibegron

Unknown severity

DB05395

The risk or severity of hypertension can be increased when Phenelzine is combined with Amibegron.

Check this interaction

Solabegron

Unknown severity

DB06190

The risk or severity of hypertension can be increased when Phenelzine is combined with Solabegron.

Check this interaction

Saralasin

Unknown severity

DB06763

The risk or severity of hypertension can be increased when Phenelzine is combined with Saralasin.

Check this interaction

Tyramine

Unknown severity

DB08841

The risk or severity of hypertension can be increased when Phenelzine is combined with Tyramine.

Check this interaction

Adrafinil

Unknown severity

DB08925

The risk or severity of hypertension can be increased when Phenelzine is combined with Adrafinil.

Check this interaction

Etilefrine

Unknown severity

DB08985

The risk or severity of hypertension can be increased when Phenelzine is combined with Etilefrine.

Check this interaction

Synephrine

Unknown severity

DB09203

The risk or severity of hypertension can be increased when Phenelzine is combined with Synephrine.

Check this interaction

Amitraz

Unknown severity

DB11373

The risk or severity of hypertension can be increased when Phenelzine is combined with Amitraz.

Check this interaction

Atipamezole

Unknown severity

DB11481

The risk or severity of hypertension can be increased when Phenelzine is combined with Atipamezole.

Check this interaction

Ractopamine

Unknown severity

DB11541

The risk or severity of hypertension can be increased when Phenelzine is combined with Ractopamine.

Check this interaction

Tulobuterol

Unknown severity

DB12248

The risk or severity of hypertension can be increased when Phenelzine is combined with Tulobuterol.

Check this interaction

Dopexamine

Unknown severity

DB12313

The risk or severity of hypertension can be increased when Phenelzine is combined with Dopexamine.

Check this interaction

Idazoxan

Unknown severity

DB12551

The risk or severity of hypertension can be increased when Phenelzine is combined with Idazoxan.

Check this interaction

Ebselen

Unknown severity

DB12610

The risk or severity of hypertension can be increased when Phenelzine is combined with Ebselen.

Check this interaction

Higenamine

Unknown severity

DB12779

The risk or severity of hypertension can be increased when Phenelzine is combined with Higenamine.

Check this interaction

Reproterol

Unknown severity

DB12846

The risk or severity of hypertension can be increased when Phenelzine is combined with Reproterol.

Check this interaction

Theodrenaline

Unknown severity

DB12927

The risk or severity of hypertension can be increased when Phenelzine is combined with Theodrenaline.

Check this interaction

Tramazoline

Unknown severity

DB13064

The risk or severity of hypertension can be increased when Phenelzine is combined with Tramazoline.

Check this interaction

Octopamine

Unknown severity

DB13251

The risk or severity of hypertension can be increased when Phenelzine is combined with Octopamine.

Check this interaction

Fenozolone

Unknown severity

DB13341

The risk or severity of hypertension can be increased when Phenelzine is combined with Fenozolone.

Check this interaction

Showing 50 of 1763 interactions

Food & lifestyle interactions

Avoid Alcohol

Avoid alcohol.

Advice

Avoid St. John's Wort. Administering phenelzine with St. John's Wort may increase the risk of serotonin syndrome.

Avoid Alcohol

Avoid tyramine-containing foods and supplements. Tyramine-containing foods and beverages can cause a sudden elevation in blood pressure or a hypertensive crisis. Foods that contain tyramine include aged cheese, ripe bananas, red wine, some alcoholic beverages (beer), cured food, pickled food, and fava beans.

Caffeine Notice

Limit caffeine intake. Excess caffeine intake can also cause a hypertensive crisis.

Toxicity & overdose

Phenelzine, as must of the monoamine oxidase inhibitors, can cause transient, mild and asymptomatic aminotransferase elevations. It has also been reported to be associated with cases of liver injury after 1-3 months of treatment.
[A31929]

How it works

Mechanism of action

The basic mechanism of action of phenelzine acts as an inhibitor and substrate of monoamine oxidase which subsequently causes an elevation in brain levels of catecholamines and serotonin. It also presents a similar structure to amphetamine which explains the effect on the uptake and release of dopamine, noradrenaline, and serotonin. Phenelzine has been reported to inhibit tyrosine aminotransferase, aromatic amino acid decarboxylase, and dopamine B-hydroxylase.[A31925]

Pharmacodynamics

The elimination of monoamine oxidase by phenelzine results in the elevation of brain amines such as 2-phenylethylamine which is a metabolite of phenelzine. These amines have then marked effects on the uptake and release of catecholamines and serotonin in nerve endings.[A31925] Phenelzine is shown to elevate brain levels of the gamma-aminobutyric acid (GABA) and alanine (ALA) as well as to inhibit the activity of the transaminases that normally metabolize these amino acids. In preclinical studies, it has been shown to be neuroprotective in cerebral ischemia.[A15753]

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Phenelzine is rapidly absorbed from the gastrointestinal tract. The decay of the drug action is not dependent on the pharmacokinetic parameters but on the rate of protein synthesis which restores the functional levels of monoamine oxidase.
[L1365]
The mean Cmax is 19.8 ng/ml and it occurs after 43 minutes of dose administration.[FDA label]

Half-life

After administration phenelzine presents a very short half-life of 11.6 hours in humans.
[L1365]

Protein binding

Unchanged phenelzine presents a high protein binding which reduced its bioavailability.T114

Volume of distribution

The volume of distribution of phenelzine is hard to determine as drugs from this kind penetrate the CNS very well into the tissue where their activity is desired.T113

Metabolism

For the metabolic studies, it is assumed that phenelzine is acetylated. Some of the metabolites of phenelzine are phenylacetic acid, 2-phenylethylamine and 4-hydroxyphenylacetic acid as major metabolites and N-acetyl-phenelzine as a minor metabolite.
[A31925]

Route of elimination

The elimination of the administered dose is mainly composed of the phenelzine metabolites, phenylacetic acid and parahydroxyphenylacetic acid that constitute 79% of the dose found in the urine in the first 96 hours.
[A31928]

Drug targets(7)

Proteins and enzymes this drug interacts with in the body

Amine oxidase [flavin-containing] A

BE0002198

MAOA

antagonist

Specific functionflavin adenine dinucleotide binding

Cellular location

Mitochondrion outer membrane

General function & pharmacology

Catalyzes the oxidative deamination of primary and some secondary amine such as neurotransmitters, with concomitant reduction of oxygen to hydrogen peroxide and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues .
PMID:18391214 PMID:20493079 PMID:24169519 PMID:8316221

Preferentially oxidizes serotonin .
PMID:20493079 PMID:24169519
Also catalyzes the oxidative deamination of kynuramine to 3-(2-aminophenyl)-3-oxopropanal that can spontaneously condense to 4-hydroxyquinoline (By similarity)

Amine oxidase [flavin-containing] B

BE0002196

MAOB

antagonist

Specific functionelectron transfer activity

Cellular location

Mitochondrion outer membrane

General function & pharmacology

Catalyzes the oxidative deamination of primary and some secondary amines such as neurotransmitters, and exogenous amines including the tertiary amine, neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), with concomitant reduction of oxygen to hydrogen peroxide and participates in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues .
PMID:11049757 PMID:11134050 PMID:20493079 PMID:8316221 PMID:8665924

Preferentially degrades benzylamine and phenylethylamine PMID:11049757 PMID:11134050 PMID:20493079 PMID:8316221 PMID:8665924

Amine oxidase [copper-containing] 3

BE0001002

AOC3

inhibitor

Specific functioncalcium ion binding

Cellular location

Cell membrane

General function & pharmacology

Catalyzes the oxidative deamination of primary amines to the corresponding aldehydes with the concomitant production of hydrogen peroxide and ammonia .
PMID:19588076 PMID:24304424 PMID:9653080

Has a preference for the primary monoamines methylamine and benzylamine .
PMID:19588076 PMID:9653080
Could also act on 2-phenylethylamine but much less efficiently .
PMID:19588076
At endothelial cells surface can also function as a cell adhesion protein that participates in lymphocyte extravasation and recirculation by mediating the binding of lymphocytes to peripheral lymph node vascular endothelial cells in an L-selectin-independent fashion PMID:9254657 PMID:9653080

4-aminobutyrate aminotransferase, mitochondrial

BE0000253

ABAT

inhibitor

Specific function(S)-3-amino-2-methylpropionate transaminase activity

Cellular location

Mitochondrion matrix

General function & pharmacology

Catalyzes the conversion of gamma-aminobutyrate and L-beta-aminoisobutyrate to succinate semialdehyde and methylmalonate semialdehyde, respectively .
PMID:10407778 PMID:15528998
Can also convert delta-aminovalerate and beta-alanine (By similarity)

Alanine aminotransferase 1

BE0000667

GPT

inhibitor

Specific functionL-alanine

Cellular location

Cytoplasm

General function & pharmacology

Catalyzes the reversible transamination between alanine and 2-oxoglutarate to form pyruvate and glutamate. Participates in cellular nitrogen metabolism and also in liver gluconeogenesis starting with precursors transported from skeletal muscles (By similarity)

Metabolizing enzymes(10)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP2C19Cytochrome P450 2C19

inhibitor

CYP2C8Cytochrome P450 2C8

inhibitor

CYP3A4Cytochrome P450 3A4

inhibitor

CYP3A5Cytochrome P450 3A5

inhibitor

CYP3A7Cytochrome P450 3A7

inhibitor

CYP2D6Cytochrome P450 2D6

inhibitor

CYP3A7Cytochrome P450 3A7 · Cytochrome P450 3A Subfamily

inhibitor

MAOAAmine oxidase [flavin-containing] A

substrate

MAOBAmine oxidase [flavin-containing] B

substrate

CYP2E1Cytochrome P450 2E1

inducer

Scientific references(9)

Nolen W.A.

Review for "Effectiveness and safety of monoamine oxidase inhibitor treatment for bipolar depression versus unipolar depression: an exploratory case cohort study". 2022. doi: 10.

1111/acps

13518/v1/review1

PMID: 14574774 DOI: 10.1111/acps.13518/v1/review1

Sowa B.N., Holt A., Todd K.G., Baker G.B.

Amine Oxidase Inhibitors and Development of Neuroprotective Drugs.

Current Neuropharmacology

20042(2):153-168. doi: 10.2174/1570159043476800

PMID: 15462176 DOI: 10.2174/1570159043476800

Todd K.G., Baker G.B.

Neurochemical effects of the monoamine oxidase inhibitor phenelzine on brain GABA and alanine: A comparison with vigabatrin.

Journal of Pharmacy & Pharmaceutical Sciences

200811(2):14. doi: 10.18433/j34s38

PMID: 19203467 DOI: 10.18433/j34s38

Singh T., Williams K.

Atypical Depression: Category or Specifier?.

The Journal of Clinical Psychiatry

200667(06):996-997. doi: 10.4088/jcp.v67n0619c

PMID: 21103169 DOI: 10.4088/jcp.v67n0619c

Winokur G., Black D.W., Nasrallah A.

Neurotic depression: a diagnosis based on preexisting characteristics.

European Archives of Psychiatry and Neurological Sciences

1987236(6):343-348. doi: 10.1007/bf00377423

PMID: 3678293 DOI: 10.1007/bf00377423

Benjaminsen S.

Primary non-endogenous depression and features attributed to reactive depression.

Journal of Affective Disorders

19813(3):245-259. doi: 10.1016/0165-0327(81)90026-4

PMID: 6456291 DOI: 10.1016/0165-0327(81)90026-4

Baker G.B., Coutts R.T., McKenna K.F., Sherry-McKenna R.L.

Failure to detect amphetamine or 1-amino-3-phenlypropane in humans or rats receiving the MAO inhibitor tranylcypromine.

Journal of Affective Disorders

200061(1-2):23-29. doi: 10.1016/s0165-0327(99)00188-3

PMID: 1362653 DOI: 10.1016/s0165-0327(99)00188-3

Robinson D.S., Cooper T.B., Jindal S.P., Corcella J., Lutz T.

Metabolism and Pharmacokinetics of Phenelzine.

Journal of Clinical Psychopharmacology

19855(6):333-337. doi: 10.1097/00004714-198505060-00005

PMID: 4066998 DOI: 10.1097/00004714-198505060-00005

Friedrich M.E., Akimova E., Huf W., Konstantinidis A., Papageorgiou K., Winkler D., Toto S., Greil W., Grohmann R., Kasper S.

Drug-Induced Liver Injury during Antidepressant Treatment: Results of AMSP, a Drug Surveillance Program.

International Journal Neuropsychopharmacol

2016 Apr 2019(4). pii: pyv126. doi: 10.1093/ijnp/pyv126. Print 2016 Apr

PMID: 26721950 DOI: 10.1093/ijnp/pyv126

ATC classification(1 code)

ATC N06AF03

Affected organisms(1)

Humans and other mammals

International brands(2)

Salt forms(1)

Phenelzine sulfate(DBSALT000954)

Experimental properties(4)

External resources(2)

RxList Drugs.com

Commercial products(8)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Phenelzine

DB00780

CAS number

51-71-8

UNII (FDA)

O408N561GF

InChI Key (molecular fingerprint)

RMUCZJUITONUFY-UHFFFAOYSA-N

Additional database identifiers

Drugs Product Database (DPD)

11355

ChEBI

8060

PubChem Compound

3675

PubChem Substance

46507348

KEGG Compound

C07430

KEGG Drug

D08349

ChemSpider

3547

BindingDB

50105417

PharmGKB

PA450903

Therapeutic Targets Database

DAP000578

Wikipedia

Phenelzine

ChEMBL

CHEMBL1089

ZINC

ZINC000019166991

RxCUI

8123

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6833

GenAtlas

MAOA

GeneCards

MAOA

GenBank Gene Database

M68840

GenBank Protein Database

187353

Guide to Pharmacology

2489

UniProtKB

P21397

UniProt Accession

AOFA_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6834

GenAtlas

MAOB

GeneCards

MAOB

GenBank Gene Database

S62734

GenBank Protein Database

398415

Guide to Pharmacology

2490

UniProtKB

P27338

UniProt Accession

AOFB_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:550

GenAtlas

AOC3

GeneCards

AOC3

GenBank Gene Database

U39447

GenBank Protein Database

1399032

Guide to Pharmacology

2767

UniProtKB

Q16853

UniProt Accession

AOC3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:23

GenAtlas

ABAT

GeneCards

ABAT

GenBank Gene Database

L32961

GenBank Protein Database

602705

Guide to Pharmacology

2464

UniProtKB

P80404

UniProt Accession

GABT_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4552

GenAtlas

GPT

GeneCards

GPT

GenBank Gene Database

U70732

GenBank Protein Database

1763096

UniProtKB

P24298

UniProt Accession

ALAT1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:18062

GenAtlas

GPT2

GeneCards

GPT2

GenBank Gene Database

AY029173

GenBank Protein Database

19046894

UniProtKB

Q8TD30

UniProt Accession

ALAT2_HUMAN

GenAtlas

GAD65

GenBank Gene Database

AJ251501

GenBank Protein Database

6562440

UniProtKB

Q9UGI5

UniProt Accession

Q9UGI5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2621

GeneCards

CYP2C19

GenBank Gene Database

M61854

GenBank Protein Database

181344

Guide to Pharmacology

1328

UniProtKB

P33261

UniProt Accession

CP2CJ_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2622

GenAtlas

CYP2C8

GeneCards

CYP2C8

GenBank Gene Database

M17397

Guide to Pharmacology

1325

UniProtKB

P10632

UniProt Accession

CP2C8_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2638

GenAtlas

CYP3A5

GeneCards

CYP3A5

GenBank Gene Database

J04813

GenBank Protein Database

181346

Guide to Pharmacology

1338

UniProtKB

P20815

UniProt Accession

CP3A5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2640

GeneCards

CYP3A7

GenBank Gene Database

D00408

GenBank Protein Database

220149

UniProtKB

P24462

UniProt Accession

CP3A7_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2625

GenAtlas

CYP2D6

GeneCards

CYP2D6

GenBank Gene Database

M20403

GenBank Protein Database

181350

Guide to Pharmacology

1329

UniProtKB

P10635

UniProt Accession

CP2D6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:17450

GeneCards

CYP3A43

GenBank Gene Database

AF319634

GenBank Protein Database

12642642

UniProtKB

Q9HB55

UniProt Accession

CP343_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2638

GenAtlas

CYP3A5

GeneCards

CYP3A5

GenBank Gene Database

J04813

GenBank Protein Database

181346

Guide to Pharmacology

1338

UniProtKB

P20815

UniProt Accession

CP3A5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2640

GeneCards

CYP3A7

GenBank Gene Database

D00408

GenBank Protein Database

220149

UniProtKB

P24462

UniProt Accession

CP3A7_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6833

GenAtlas

MAOA

GeneCards

MAOA

GenBank Gene Database

M68840

GenBank Protein Database

187353

Guide to Pharmacology

2489

UniProtKB

P21397

UniProt Accession

AOFA_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6834

GenAtlas

MAOB

GeneCards

MAOB

GenBank Gene Database

S62734

GenBank Protein Database

398415

Guide to Pharmacology

2490

UniProtKB

P27338

UniProt Accession

AOFB_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2631

GeneCards

CYP2E1

GenBank Gene Database

J02625

GenBank Protein Database

181360

Guide to Pharmacology

1330

UniProtKB

P05181

UniProt Accession

CP2E1_HUMAN

International reference pricing

3 formulations

Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.

From $0.39/tablet

To $51.00/g

Nardil 15 mg Tablet

$0.39/tablet

Nardil 15 mg tablet

$0.95/tablet

Phenelzine sulfate powder

$51.00/g

Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 26 days ago(8 Mar 2026)

Back to medicines

Phenelzine 15mg tablets

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

British National Formulary

NICE clinical guidance(3)

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clinical essentials

Pharmacology

Deep science
17

Chemical identifiers

Phenelzine

Additional database identifiers

International reference pricing

DrugBank citations

Phenelzine 15mg tablets

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

Guidance (NICE / BNF)

British National Formulary

NICE clinical guidance(3)

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clinical essentials

Pharmacology

Deep science17

Chemical identifiers

Phenelzine

Additional database identifiers

International reference pricing

DrugBank citations

Deep science
17